Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synbio TechROCO:1295 -1.40%61 ROE % is 17.08% as of Jun. 2026, which is 9% above its 10-year median of 15.72. GuruFocus rates ROCO:1295 with a GF Score™ of 61/100 and a GF Value™ of NT$82.69 (Possible Value Trap). The stock has 12 warning signs investors should review. Among 1,249 Biotechnology companies, Synbio Tech ranks better than 88.39% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Synbio Tech's annualized net income for the quarter that ended in Jun. 2026 was NT$219 Mil. Synbio Tech's average Total Stockholders Equity over the quarter that ended in Jun. 2026 was NT$1,281 Mil. Therefore, Synbio Tech's annualized ROE % for the quarter that ended in Jun. 2026 was 17.08%.
The historical rank and industry rank for Synbio Tech's ROE % or its related term are showing as below:
ROCO:1295'
s ROE % Range Over the Past 10 Years
Min: 10.51 Med: 15.72 Max: 19.73
Current: 11.12
During the past 6 years, Synbio Tech's highest ROE % was 19.73%. The lowest was 10.51%. And the median was 15.72%.
ROCO:1295's ROE % is ranked better than 88.39% of 1249
companies
in the Biotechnology industry
Industry Median: -38.74
vs ROCO:1295: 11.12
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Synbio Tech ROE % Related Terms
Synbio Tech ROE % Historical Data
* Premium members only.
The historical data trend for Synbio Tech's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Synbio Tech's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synbio Tech ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Synbio Tech's ROE % distribution charts can be found below:
* The bar in red indicates where Synbio Tech's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Synbio Tech (ROCO:1295) has a ROE % of 17.08% as of Jun. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Synbio Tech and its competitors. This is near median its historical median of 15.72. Over the past decade, Synbio Tech's ROE % has ranged from 10.51 to 19.73. According to the industry distribution chart, Synbio Tech ranks #145 out of 1249 companies in the Biotechnology industry, placing it in the top 11.6%.
Is Synbio Tech's ROE % too high?
Synbio Tech's current ROE % of 17.08% is near median its 10-year median of 15.72. Over the past 10 years, this metric has ranged from a low of 10.51 to a high of 19.73. Based on the distribution chart, Synbio Tech ranks #145 out of 1249 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Synbio Tech has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Synbio Tech's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Synbio Tech ranks #145 out of 1249 companies for ROE %. This places Synbio Tech in the top 12% of its industry — outperforming the majority of peers. Historically, Synbio Tech's own ROE % has ranged from 10.51 to 19.73 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Synbio Tech and its competitors. Synbio Tech's current ROE % is 17.08%, which is near median its own 10-year median of 15.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synbio Tech stock overvalued right now?
Based on GuruFocus' analysis, Synbio Tech (ROCO:1295) is currently considered Possible Value Trap. The stock's GF Value™ is NT$82.69, compared to a current price of NT$45.65 — trading 44.8% below its estimated fair value. The current ROE % is 17.08%, which is near median its 10-year median of 15.72. Synbio Tech's overall GF Score™ is 61/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Synbio Tech (ROCO:1295), the current ROE % is 17.08% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synbio Tech (ROCO:1295) Overvalued in 2026?
Based on GuruFocus' analysis, Synbio Tech stock appears to be undervalued.
The current stock price of NT$45.65 is trading 44.8% below its estimated GF Value™ of NT$82.69.
GuruFocus considers Synbio Tech to be Possible Value Trap.
Key valuation signals for ROCO:1295:
ROE %: 17.08% (near median its 10-year median of 15.72)
GF Value™: NT$82.69 vs. price of NT$45.65 (44.8% below fair value)
No single metric tells the full story. See the ROCO:1295 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synbio Tech Inc focus on functional research and manufacturing of probiotics for human health and economic animals. It has two reportable segments, Taiwan and Mainland China Segment to engage in the production and R&D technologies of the Taiwan Segment, including the production and sales of concentrated fermentation liquid, lactobacillus plantarum solid drinks, and lactobacillus plantarum granules for animal husbandry. It generates majority of revenue from Taiwan segment includes production and sale of lactobacillus plantarum powder, lactobacillus plantarum fermentation derivative products, probiotics dietary supplements, probiotics products for pets and economic animals, and probiotics products. It has presence in Taiwan, China, Southeast Asia, and Others.
61GF Score
Get the complete analysis for ROCO:1295
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1295 has been successfully added to your 
